DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site, 2021 Q3 to 2026 Q2
- $524M
- 88 holdings
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
AUM over time
Book
| XBI, SPDR S&P Biotech ETF | Reduce −1.0% | 397,505 | $90.06 | $36M | −4,000 | −$3.9M | |
| STXS, Stereotaxis | Hold | 13,680,554 | $2.28 | $31M | — | — | |
| RVMD, Revolution Medicines | Add +21.9% | 631,176 | $43.74 | $28M | +113,182 | +$4.1M | |
| ATRC, Atricure | Hold | 641,673 | $30.56 | $20M | — | — | |
| Merus | Add +9.5% | 451,804 | $42.05 | $19M | +39,231 | −$1.6M | |
| CYTK, Cytokinetics | Hold | 398,100 | $47.04 | $19M | — | — | |
| ASND, Ascendis Pharma A/s | Add +15.4% | 103,355 | $137.67 | $14M | +13,783 | +$855K | |
| AXGN, Axogen | Reduce −9.5% | 846,882 | $16.48 | $14M | −89,012 | +$835K | |
| NDAQ, iShares Nasdaq Biotech Indx | Hold | 102,500 | $132.21 | $14M | — | — | |
| Blueprint Medicines | Add +23.0% | 149,763 | $87.22 | $13M | +28,000 | +$1.8M | |
| IDYA, Ideaya Biosciences | Add +5.8% | 498,827 | $25.70 | $13M | +27,417 | −$2.1M | |
| XENE, Xenon Pharmaceuticals | Hold | 273,739 | $39.20 | $11M | — | — | |
| NBIX, Neurocrine Biosciences | Add +2.9% | 71,615 | $136.50 | $9.8M | +2,000 | +$1.8M | |
| DAWN | Reduce −2.5% | 731,363 | $12.67 | $9.3M | −19,000 | −$1.2M | |
| BHVN, Biohaven | Add +17.7% | 220,235 | $37.35 | $8.2M | +33,105 | −$1.1M | |
| TNDM, Tandem Diabetes Care | Add +9.3% | 223,208 | $36.02 | $8M | +19,000 | −$621K | |
| SNDX, Syndax Pharmaceuticals | Add +2.9% | 542,002 | $13.22 | $7.2M | +15,300 | −$3M | |
| Kalvista Pharmaceuticals | Add +12.2% | 811,678 | $8.47 | $6.9M | +88,000 | −$1.5M | |
| URGN, Urogen | Add +7.3% | 492,515 | $10.65 | $5.2M | +33,600 | −$583K | |
| DXCM, DexCom | Hold | 65,552 | $77.77 | $5.1M | — | — | |
| BCRX, Biocryst Pharmaceuticals | Hold | 667,000 | $7.52 | $5M | — | — | |
| EWTX, Edgewise Therapeutics | Reduce −17.9% | 187,140 | $26.70 | $5M | −40,766 | −$1.1M | |
| TELA, Tela Bio | New | 1,441,029 | $3.02 | $4.4M | +1,441,029 | +$4.4M | |
| PRQR, Proqr Therapeutics | Add +73.1% | 1,567,561 | $2.65 | $4.2M | +661,979 | +$2.5M | |
| KURA, Kura Oncology | Add +9.8% | 448,368 | $8.71 | $3.9M | +40,000 | −$4.1M | |
| RCUS, Arcus Biosciences | Reduce −1.0% | 254,217 | $14.89 | $3.8M | −2,500 | −$140K | |
| LKFT, Galapagos | Hold | 130,175 | $27.50 | $3.6M | — | — | |
| ALKS, Alkermes | Hold | 120,700 | $28.76 | $3.5M | — | — | |
| PODD, Insulet | Reduce −22.0% | 12,400 | $261.07 | $3.2M | −3,500 | −$463K | |
| ATXS, Astria Therapeutics | Add +17.9% | 299,775 | $8.94 | $2.7M | +45,610 | −$118K | |
| IMVT, Immunovant | Add +107.7% | 107,996 | $24.77 | $2.7M | +56,000 | +$1.2M | |
| ALLO, Allogene Therapeutics | Add +18.1% | 1,240,118 | $2.13 | $2.6M | +190,000 | −$299K | |
| VKTX, Viking Therapeutics | Reduce −48.6% | 64,516 | $40.24 | $2.6M | −61,100 | −$5.4M | |
| LXEO, Lexeo Therapeutics | Add +56.9% | 393,083 | $6.58 | $2.6M | +142,500 | +$321K | |
| ARAY, Accuray | Hold | 1,222,358 | $1.98 | $2.4M | — | — | |
| Keros Therapeutics | Add +76.7% | 130,316 | $15.83 | $2.1M | +56,562 | −$2.2M | |
| INGN, Inogen | Hold | 208,790 | $9.17 | $1.9M | — | — | |
| STOK, Stoke Therapeutics | Reduce −17.5% | 171,097 | $11.03 | $1.9M | −36,330 | −$662K | |
| BCAX, Bicara Therapeutics | New | 105,500 | $17.42 | $1.8M | +105,500 | +$1.8M | |
| BWAY, Brainsway | Reduce −23.1% | 193,208 | $9.43 | $1.8M | −58,138 | −$500K | |
| MLYS, Mineralys Therapeutics | Hold | 146,500 | $12.31 | $1.8M | — | — | |
| Immatics | Add +69.0% | 245,000 | $7.11 | $1.7M | +100,000 | +$88K | |
| ALEC, Alector | Hold | 912,928 | $1.89 | $1.7M | — | — | |
| IPSC, Century Therapeutics | Hold | 1,704,232 | $1.01 | $1.7M | — | — | |
| BCYC, Bicycle Therapeutics | Reduce −1.1% | 120,799 | $14.00 | $1.7M | −1,401 | −$1.1M | |
| Iteos Therapeutics | Add +16.6% | 188,347 | $7.68 | $1.4M | +26,763 | −$203K | |
| LRMR, Larimar Therapeutics | Reduce −24.9% | 371,434 | $3.87 | $1.4M | −122,840 | −$1.8M | |
| Regulus Therapeutics | Reduce −2.2% | 875,200 | $1.58 | $1.4M | −20,000 | −$23K | |
| AUTL, Autolus Therapeutics | Add +20.5% | 586,667 | $2.35 | $1.4M | +100,000 | −$388K | |
| Gossamer Bio | Reduce −0.7% | 1,409,262 | $0.9046 | $1.3M | −10,000 | −$125K | |
| 2seventy Bio | Reduce −31.9% | 429,252 | $2.94 | $1.3M | −200,777 | −$1.7M | |
| Holding | Add +85.9% | 2,511,374 | $0.5025 | $1.3M | +1,160,666 | +$39K | |
| NGNE, Neurogene | Add +562.4% | 51,500 | $22.86 | $1.2M | +43,725 | +$851K | |
| Mediwound | Hold | 64,479 | $17.80 | $1.1M | — | — | |
| ALGN, Align Technology | New | 5,500 | $208.51 | $1.1M | +5,500 | +$1.1M | |
| BNTX, Biontech | Hold | 8,500 | $113.95 | $969K | — | — | |
| GPCR, Structure Therapeutics | Add +4.4% | 35,500 | $27.12 | $963K | +1,500 | −$530K | |
| SPRY, Ars Pharmaceuticals | Reduce −40.1% | 88,790 | $10.55 | $937K | −59,504 | −$1.2M | |
| CMPS, Compass Pathways | Hold | 243,210 | $3.78 | $919K | — | — | |
| TSHA, Taysha Gene Therapies | New | 522,500 | $1.73 | $904K | +522,500 | +$904K | |
| Polypid | Reduce −5.6% | 291,273 | $3.04 | $885K | −17,224 | −$176K | |
| FHTX, Foghorn Therapeutics | Add +395.7% | 186,717 | $4.72 | $881K | +149,053 | +$531K | |
| PVLA, Palvella Therapeutics | New | 71,452 | $12.00 | $857K | +71,452 | +$857K | |
| Sutro Biopharma | Add +32.6% | 437,079 | $1.84 | $804K | +107,500 | −$336K | |
| CNTA, Centessa Pharmaceuticals | Reduce −60.6% | 47,453 | $16.75 | $795K | −72,898 | −$1.1M | |
| VIR, Vir Biotechnology | New | 100,000 | $7.34 | $734K | +100,000 | +$734K | |
| Compugen | Hold | 447,202 | $1.53 | $684K | — | — | |
| ACRV, Acrivon Therapeutics | Hold | 112,414 | $6.02 | $677K | — | — | |
| Sage Therapeutics | Hold | 108,200 | $5.43 | $588K | — | — | |
| Adicet Bio | Hold | 600,000 | $0.9620 | $577K | — | — | |
| Masimo | Hold | 3,000 | $165.30 | $496K | — | — | |
| AQST, Aquestive Therapeutics | Reduce −78.5% | 127,000 | $3.56 | $452K | −462,561 | −$2.5M | |
| APRE, Aprea Therapeutics | Hold | 137,174 | $3.29 | $451K | — | — | |
| ADCT, Adc Therapeutics | Add +9.8% | 224,081 | $1.99 | $446K | +20,000 | −$197K | |
| CATX, Perspective Therapeutics | Reduce −43.5% | 130,169 | $3.19 | $415K | −100,153 | −$2.7M | |
| BDTX | Add +12.0% | 140,000 | $2.14 | $300K | +15,000 | −$244K | |
| Biomx | Hold | 401,136 | $0.7301 | $293K | — | — | |
| Acelyrin | Reduce −85.4% | 87,989 | $3.14 | $276K | −514,905 | −$2.7M | |
| CMPX, Compass Therapeutics | Add +35.5% | 158,394 | $1.45 | $230K | +41,512 | +$15K | |
| Nevro | Hold | 38,000 | $3.72 | $141K | — | — | |
| Spero Therapeutics | Hold | 125,000 | $1.03 | $129K | — | — |
Showing top 50 of 81 by value
Exits / last held
Gone since 2024 Q3, shown at their last reported size.
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Nyxoah | Exit | 0 | $9.55 | $1M | −108,108 | −$1M | |
| GRAL, Grail | Exit | 0 | $13.75 | $671K | −48,800 | −$671K | |
| Tourmaline Bio | Exit | 0 | $25.69 | $491K | −19,110 | −$491K | |
| VSTM, Verastem | Exit | 0 | $2.99 | $382K | −127,700 | −$382K | |
| Adaptimmune Therapeutics | Exit | 0 | $0.9500 | $324K | −341,064 | −$324K | |
| ANRO, Alto Neuroscience | Exit | 0 | $11.42 | $306K | −26,786 | −$306K | |
| Neuronetics | Exit | 0 | $0.7586 | $238K | −313,717 | −$238K | |
| Karyopharm Therapeutics | Exit | 0 | $0.8304 | $160K | −192,678 | −$160K |
Filings history
20 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site, 2021 Q3 to 2026 Q2